DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced an oral podium presentation and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2023), being held May 30 – June 2, 2023, in Miami, Fla.
Oral Podium Presentation Details
| Title: | An Open-Label Trial Assessing Short- And Long-Term Tolerability and Efficacy of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE) and Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in the Treatment of Behavioral Symptoms in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017) |
| Date: | Tuesday, May 30, 2023 |
| Session: | Pharmaceutical Pipeline Session |
| Time: | 3:20 p.m. – 3:30 p.m. ET |
| Location: | Salon 3 – The Loews Miami Beach |
| Title: | An Open-Label Trial Assessing Short- and Long-Term Tolerability and Efficacy of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE) [W49] |
| Title: | Long-term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in the Treatment of Behavioral Symptoms in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017) [W50] |
| Session: | Poster Session I |
| Date: | Wednesday, May 31, 2023 |
| Time: | 11:15 a.m. – 1:00 p.m. ET |
| Location: | Salon 4 – The Loews Miami Beach |
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.